id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12708 R53673 |
Bjørk (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
7.97 [5.07;12.52] C excluded (control group) |
64/2,421 27/7,950 | 91 | 2,421 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12519 R53674 |
Bjørk (Valproate) (Controls unexposed NOS) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
4.77 [3.73;6.10] excluded (control group) |
64/2,421 16,384/4,463,879 | 16,448 | 2,421 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12707 R53675 |
Bjørk (Valproate) (Controls unexposed, sick) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 4.20 [3.11;5.66] C | 64/2,421 139/21,634 | 203 | 2,421 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15275 R62802 |
Thomas (Valproate), 2022 | Full-scale IQ - Wechsler Intelligence Scale for Children or Adult - Ages 13 to 21 years (mean of 16.5 ± 2.2 years) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No extrapolated (cont. endpoint) | 1.31 [0.38;4.52] | -/33 -/11 | - | 33 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9374 R53666 |
Bromley (Valproate), 2016 | Full-scale IQ <85 (Wechsler Preschool and Primary Scale of Intelligence (WPPSI) / Wechsler Intelligence Scale for Children (WISC)) (5-9 years old) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 4.11 [1.04;16.19] C | 9/47 3/55 | 12 | 47 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9371 R53663 |
Baker (Valproate) (Controls exposed to Lamotrigine, sick), 2015 | Mean child Full scale IQ - Differential ability scales (DAS) (age mean >6 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No extrapolated (cont. endpoint) |
3.48 [1.49;8.14] excluded (control group) |
-/51 -/29 | - | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9372 R53664 |
Baker (Valproate) (Controls unexposed, disease free), 2015 | IQ <85 - Differential ability scales (DAS) (age mean >6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: Yes |
6.83 [3.02;15.45] excluded (control group) |
-/51 -/210 | - | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9373 R53665 |
Baker (Valproate) (Controls unexposed, sick), 2015 | Mean child Full scale IQ - Differential ability scales (DAS) (age mean >6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No extrapolated (cont. endpoint) | 3.76 [1.54;9.19] | -/51 -/25 | - | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9414 R53670 |
Meador (Valproate), 2013 | IQ <85 (DAS) (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 7.02 [1.42;34.66] C | 8/49 2/74 | 10 | 49 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9415 R53671 |
Nadebaum (Valproate), 2011 | Full-scale child's IQ (WISC) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No extrapolated (cont. endpoint) | 5.19 [1.20;22.40] | -/23 -/9 | - | 23 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9421 R53678 |
Titze (Valproate) (Controls unexposed, disease free), 2008 | Learning disability (IQ<70) (German versions of the revised Wechsler Intelligence Scales for children and for adults) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
19.40 [0.31;1195.39] C excluded (control group) |
0/3 0/49 | 0 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9422 R53679 |
Titze (Valproate) (Controls unexposed, sick), 2008 | Learning disability (IQ<70) (German versions of the revised Wechsler Intelligence Scales for children and for adults) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.53 [0.05;49.80] C | 0/3 1/13 | 1 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9428 R53672 |
Viinikainen (Valproate) b, 2006 | Full Scale IQ (FIQ) < 1SD (Wechsler Intelligence Scale for Children (WISC III)) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No Matched | 18.33 [0.88;380.72] C | 5/13 0/13 | 5 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9429 R53680 |
Vinten (Valproate), 2005 | IQ score <69 (Wechsler Intelligence Scale for Children (WISC III)) (Aged between 6 and 16 years) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 3.47 [1.14;10.56] C | 9/41 6/80 | 15 | 41 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9278 R53662 |
Adab (Valproate), 2004 | Mean Full Scale IQ (Wechsler Intelligence Scale for Children (WISC)) (Aged between 6 and 16 years) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No extrapolated (cont. endpoint) | 1.26 [0.64;2.50] | -/41 -/80 | - | 41 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9401 R53667 |
Gaily (Valproate) (Controls unexposed, disease free), 2004 | Full scale IQ (Wechsler Preschool and Primary Scale of Intelligence Revised (WPPSI-R) or Wechsler Intelligence Scale for Children Revised (WISC-R)) | 2nd and/or 3rd trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No extrapolated (cont. endpoint) |
2.40 [0.85;6.75] excluded (control group) |
-/13 -/140 | - | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9402 R53668 |
Gaily (Valproate) (Controls unexposed, sick), 2004 | Full scale IQ (Wechsler Preschool and Primary Scale of Intelligence Revised (WPPSI-R) or Wechsler Intelligence Scale for Children Revised (WISC-R)) | 2nd and/or 3rd trimester | prospective cohort | unexposed, sick | Adjustment: No extrapolated (cont. endpoint) | 1.82 [0.59;5.59] | -/13 -/45 | - | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 11 studies | 2.99 [2.00;4.48] | 246 | 2,735 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Controls unexposed, sick) (Mixed indications; 2: Valproate; 3: Valproate; 4: Valproate) (Controls unexposed, sick; 5: Valproate; 6: Valproate; 7: Valproate) (Controls unexposed, sick; 8: Valproate) ; 9: Valproate; 10: Valproate; 11: Valproate) (Controls unexposed, sick;
Asymetry test p-value = 0.6218 (by Egger's regression)
slope=1.3227 (0.2538); intercept=-0.3288 (0.6437); t=0.5108; p=0.6218
excluded 9401, 9421, 9371, 9372, 12708, 12519